Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.

about

Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.

Item

http://www.wikidata.org/entity/Q40603398

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Population pharmacokinetic mod ...... ns in HIV-1 infected patients.

@en

type

Item

label

Population pharmacokinetic mod ...... ns in HIV-1 infected patients.

@en

prefLabel

Population pharmacokinetic mod ...... ns in HIV-1 infected patients.

@en

P1476

Population pharmacokinetic mod ...... ons in HIV-1 infected patients

@en

P2093

Bonaventura Clotet

http://www.w3.org/2001/XMLSchema#string

Cristina Miranda

http://www.w3.org/2001/XMLSchema#string

Javier A Estévez

http://www.w3.org/2001/XMLSchema#string

Samandhy Cedeño

http://www.w3.org/2001/XMLSchema#string

P2860

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Handling data below the limit of quantification in mixed effect models.

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir.

Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients

Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies

Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection

Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.

Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients

Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic

Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin.

P304

1528-1538

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BCP.13072

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

José Moltó

Marta Valle

P577

2016-09-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27447851

http://www.w3.org/2001/XMLSchema#string

P932

5099552

http://www.w3.org/2001/XMLSchema#string